Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Pitney Bowes Q2 2025 Earnings Call - Aggressive Buybacks After Presort Customer Losses, Leverage Below 3x
Pitney Bowes used this quarter to reset the narrative, leaning hard into buybacks and internal surgery after acknowledging an avoidable revenue hit in Presort. Management confirmed a $400 million buyb...
- Kurt Wolff is now CEO and emphasized rapid, efficiency-driven change; Paul Evans moved from board chair to CFO, giving up his board seat to take the operating role.
- Board increased share repurchase authorization from $150,000,000 to $400,000,000, and the company nearly exhausted the previous $150,000,000 authorization via aggressive buys over the prior 120 days.
- Adjusted leverage ratio is below 3.0x, which management says replenishes restricted-payment baskets and materially increases flexibility for buybacks, dividends, and debt actions.
- +12 more takeaways
Bausch Health Q2 2025 Earnings Call - Ninth Straight Quarter of Revenue and Adjusted EBITDA Growth; Guidance Reaffirmed
Bausch Health delivered a clean, workmanlike quarter: nine consecutive quarters of year over year revenue and adjusted EBITDA growth for Bausch Health excluding Bausch and Lomb, and management reaffir...
- Bausch Health excluding Bausch and Lomb posted its ninth consecutive quarter of year over year revenue and adjusted EBITDA growth; Q2 revenue $1.252B (up 5%), adjusted EBITDA $676M (up 10%).
- Company reaffirmed full year 2025 guidance for Bausch Health excluding Bausch and Lomb: revenue $4.95B–$5.10B, adjusted EBITDA $2.625B–$2.725B, adjusted operating cash flow $825M–$875M.
- Consolidated Q2 revenue was $2.53B, adjusted EBITDA $871M (up 5% year over year), and adjusted operating cash flow $442M.
- +12 more takeaways
CurbLine Properties Q2 2025 Earnings Call - Acquisition Acceleration Drives Guidance Raise
CurbLine used the quarter to sprint, not trot. Management closed an aggressive string of deals and pushed 2025 OFFO guidance higher, leaning on what it calls the capital efficiency and leasing liquidi...
- Company accelerated acquisitions, reporting $415 million of properties acquired in Q2 and Q3-to-date and over $750 million of assets acquired since the spin-off.
- Closed a 23-property portfolio for $159 million; Q2 activity included 19 properties for $155 million via 17 separate transactions, with deals concentrated in Houston, Chicago, Phoenix and Atlanta.
- Raised 2025 OFFO guidance to $1.00–$1.03 per share, underpinned by an assumed ~$700 million of full-year investments funded roughly 50/50 with debt and cash.
- +12 more takeaways
Impinj Second Quarter 2025 Earnings Call - M800 and Gen2X Drive Revenue Beat and Record Adjusted EBITDA
Impinj beat the quarter, delivering $97.9 million in revenue, a 32% sequential rise, and a new quarterly record adjusted EBITDA of $27.6 million. The beat was driven by strong endpoint IC demand, M800...
- Revenue of $97.9 million, up 32% sequentially from Q1 2025, down 4% year over year from Q2 2024.
- Endpoint IC revenue was $84.6 million, up 38% sequentially and down 5% year over year; endpoint IC product revenue excluding licensing grew 12% sequentially and declined 8% year over year.
- Systems revenue was $13.3 million, up 2% sequentially and up 1% year over year, driven by reader and gateway demand.
- +14 more takeaways
Bank of Hawaii Second Quarter 2025 Earnings Call - Margin Reversion Drives NIM, NII and EPS Growth
Bank of Hawaii posted another steady quarter: net income of $47.6 million and diluted EPS of $1.60, driven by a fifth straight quarter of net interest income and margin expansion as fixed-rate assets ...
- Net income $47.6 million, diluted EPS $1.60, up $0.09 QoQ and $3.7 million in absolute dollars versus linked quarter.
- Net interest income and net interest margin expanded for the fifth consecutive quarter; NIM improved about 7 basis points in the quarter.
- Fixed-rate assets of $572 million rolled off at a 4% rate and were reinvested at a 6.3% roll-on rate, the main driver of margin accretion this quarter.
- +16 more takeaways
Franklin Electric Q2 2025 Earnings Call - Record revenue and margins, company holds guide to fund supply chain investments and faces ~$1 non-cash pension hit
Franklin Electric posted a clean quarter, setting company records for revenue, operating income, and EPS while managing tariff and commodity noise with pricing and productivity. Consolidated sales ros...
- Consolidated Q2 sales were $587.4 million, up 8% year over year, driven by volume, price, and recent acquisitions.
- GAAP EPS for Q2 was $1.31, up $0.06 versus Q2 2024 ($1.26), and the company reported record revenue, operating income, and EPS for the period.
- Consolidated gross margin fell 70 basis points to 36.1%, while consolidated operating margin improved to 15.0% from 14.6% a year ago.
- +12 more takeaways
Eagle Materials Q1 FY2026 Earnings Call - Record Revenue, Cement and Aggregates Volumes Rise as Maintenance Pressures Margins
Eagle Materials opened fiscal 2026 with a solid quarter: record revenue of $634.7 million and EPS of $3.76, even as higher operating costs tied to annual maintenance and a JV ramp weighed on margins. ...
- Record Q1 revenue of $634.7 million, up 4% year over year.
- Diluted EPS $3.76, down 5% year over year, driven largely by lower cement earnings and higher operating costs.
- Consolidated revenue ex-acquisitions rose 2%, indicating organic growth alongside recent quarry integrations.
- +12 more takeaways
GeneDx Q2 2025 Earnings Call - Core Business Surges Past $100M, Guidance Raised as Reimbursement and Volume Momentum Accelerate
GeneDx printed a breakout quarter, crossing $100 million in revenue and leaning on its core exome and genome business to drive the beat. Q2 revenue was $102.7 million, with exome and genome revenue hi...
- Q2 revenue $102.7 million, up 49% year over year, the first quarter above $100 million driven by core business strength.
- Exome and genome revenue was a record $85.9 million in Q2, up 69% YoY; total tests in the quarter were 23,102, up 28% YoY.
- Average reimbursement (ASP) for exome and genome in Q2 was $3,718 per test, up from about $3,400 last quarter; management says this reflects durable improvements, not a one-time item.
- +16 more takeaways
Repligen Corporation Q2 2025 Earnings Call - Portfolio momentum drives raise to 2025 revenue outlook despite gene-therapy headwind
Repligen posted a strong Q2, led by Chromatography and Filtration, and raised its 2025 revenue outlook as broad-based demand and order momentum more than offset a one-off gene-therapy program headwind...
- Q2 revenue $182 million, up 15% reported, 11% organic and 17% organic non-COVID growth.
- Company raised 2025 revenue guidance to $715 million to $735 million, increasing the organic growth midpoint; organic revenue growth guidance now 10.5% to 13.5% (12.5% to 15.5% organic non-COVID).
- Orders grew over 20% year over year and high teens organically; this marks eight straight quarters where orders exceeded non-COVID revenue and five straight quarters of sequential order growth.
- +14 more takeaways
Commvault Systems Inc. Q1 FY2026 Earnings Call - SaaS ARR Surge Nears $1B Total ARR, Raises FY26 Guide
Commvault delivered a standup quarter, propelled by a blistering SaaS ramp and a best-ever land and expand performance. Total ARR climbed 24% to $996 million, subscription ARR rose 33% to $844 million...
- Total ARR rose 24% year over year to $996 million, approaching the $1 billion milestone.
- Subscription ARR increased 33% to $844 million, now 85% of total ARR versus 79% a year ago.
- SaaS ARR surged 63% to $307 million, a clear driver of the quarter and a main reason management accelerated its ARR targets.
- +12 more takeaways